News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
New role strengthens Quantori’s global leadership position in data science & digital IT
The covid health center will be managed and administered by the district administration of Ballari
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Subscribe To Our Newsletter & Stay Updated
